Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-024646
Filing Date
2025-08-18
Accepted
2025-08-18 17:00:18
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10489
2 EX-1 ex1.htm EX-1 13711
  Complete submission text file 0001641172-25-024646.txt   26007
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Subject) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90199 | Film No.: 251228603
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 3455 PEACHTREE ROAD NE, 5TH FLOOR ATLANTA GA 30326
Business Address 3455 PEACHTREE ROAD NE, 5TH FLOOR ATLANTA GA 30326 917-657-2249
Trails Edge Capital Partners, LP (Filed by) CIK: 0002077247 (see all company filings)

EIN.: 331689212 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G